Correlation Between Biotechnology Portfolio and Dreyfus Technology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Biotechnology Portfolio and Dreyfus Technology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biotechnology Portfolio and Dreyfus Technology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biotechnology Portfolio Biotechnology and Dreyfus Technology Growth, you can compare the effects of market volatilities on Biotechnology Portfolio and Dreyfus Technology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biotechnology Portfolio with a short position of Dreyfus Technology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biotechnology Portfolio and Dreyfus Technology.

Diversification Opportunities for Biotechnology Portfolio and Dreyfus Technology

0.06
  Correlation Coefficient

Significant diversification

The 3 months correlation between Biotechnology and Dreyfus is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Biotechnology Portfolio Biotec and Dreyfus Technology Growth in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dreyfus Technology Growth and Biotechnology Portfolio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biotechnology Portfolio Biotechnology are associated (or correlated) with Dreyfus Technology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dreyfus Technology Growth has no effect on the direction of Biotechnology Portfolio i.e., Biotechnology Portfolio and Dreyfus Technology go up and down completely randomly.

Pair Corralation between Biotechnology Portfolio and Dreyfus Technology

Assuming the 90 days horizon Biotechnology Portfolio Biotechnology is expected to generate 0.66 times more return on investment than Dreyfus Technology. However, Biotechnology Portfolio Biotechnology is 1.51 times less risky than Dreyfus Technology. It trades about 0.04 of its potential returns per unit of risk. Dreyfus Technology Growth is currently generating about -0.05 per unit of risk. If you would invest  1,936  in Biotechnology Portfolio Biotechnology on December 25, 2024 and sell it today you would earn a total of  41.00  from holding Biotechnology Portfolio Biotechnology or generate 2.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Biotechnology Portfolio Biotec  vs.  Dreyfus Technology Growth

 Performance 
       Timeline  
Biotechnology Portfolio 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Biotechnology Portfolio Biotechnology are ranked lower than 2 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly strong basic indicators, Biotechnology Portfolio is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Dreyfus Technology Growth 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Dreyfus Technology Growth has generated negative risk-adjusted returns adding no value to fund investors. In spite of fairly strong fundamental indicators, Dreyfus Technology is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Biotechnology Portfolio and Dreyfus Technology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Biotechnology Portfolio and Dreyfus Technology

The main advantage of trading using opposite Biotechnology Portfolio and Dreyfus Technology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biotechnology Portfolio position performs unexpectedly, Dreyfus Technology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dreyfus Technology will offset losses from the drop in Dreyfus Technology's long position.
The idea behind Biotechnology Portfolio Biotechnology and Dreyfus Technology Growth pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities